research

SACRAMENTO — Three state bond measures are on California’s November ballot. You probably haven’t paid much attention to them. So here’s my read on these big-ticket proposals.

One is a no-brainer “yes.” It would help middle-class Californians buy a new home by allowing them to borrow most of the down payment. And it wouldn’t cost taxpayers a dime. That’s Proposition 37.

Another housing measure is probably worthwhile, but gives me pause because it accommodates too many interests in order to attract broad political support. And it burns a barrel of money. That’s Proposition 1.

The third proposal would fund important medical research. But I wince because it was written to largely benefit one institute that was co-founded and is headed by the measure’s chief backer. That’s Proposition 38.

Propositions 1 and 38 combined would add $18.4 billion to the state’s general fund bond debt, which already is about $80 billion, according to the nonpartisan Legislative Analyst‘s Office.

Plus, there is $40 billion in previously authorized bonds waiting to be sold. The new bond proposals would cost the state at least $1 billion annually for 20 to 25 years. Taxpayers are paying about $6 billion annually to retire state bonds.

Bonds are boring, but they’re also tax eaters. So we should pay some attention before voting on them.

“People think about bonds as free money. And, of course, they’re not,” says Mark Baldassare, polling director for the Public Policy Institute of California. “People don’t think bonds are going to raise their taxes.”

But most bonds are repaid by the state’s general fund, the main cash box that finances major programs such as education, healthcare, prisons and fighting wildfires. Bond debt has No. 1 dibs on the money. When revenue runs short — a common dilemma in Sacramento — other programs must be cut or taxpayers are hit harder. So bonds aren’t necessarily tax-free.

Baldassare released a PPIC poll last week that found a majority of likely voters supporting all three bond measures — especially Proposition 37 to ease homebuyers’ down payments.

The pollster noted that fall election campaigns are just starting and opposition arguments could reduce support for the measures.

But there’s no organized opposition to the two housing proposals. And although the medical research measure has some outspoken critics, there’s no money for an opposition campaign.

OK, a few specifics on each measure.

Proposition 37 is a taxpayer freebie, a $25-billion bond repaid solely by homebuyer beneficiaries. Here’s how it would work:

Middle-income people could pay 3% down on their home purchases rather than the normal 20%. They’d borrow the other 17% as a second mortgage and repay it along with the first mortgage.

The proposition defines middle class as household income that’s less than double the median for the area. Statewide, that income ceiling would be around $200,000 but would vary greatly by locale.

The purchased dwelling must be a brand-new home, whether stand-alone or a condo. That’s to increase the housing supply and create construction jobs. Politically, it gains the support of developers and unions.

No vacation home. It must be owner-occupied full-time. And the buyer must be a California resident.

The state’s sale of revenue bonds would create the down-payment pot. Regular lending institutions would arrange the loans and charge minimum fees. Loan repayments would replenish the pot and make it self-sustaining.

This was the brainchild of Bob Hertzberg, a former Democratic Assembly speaker and Senate majority leader from the San Fernando Valley.

Hertzberg tried several times to sell his proposal to the Legislature, but lawmakers wanted to juice it up with their own pet ideas. “I couldn’t get something just focused on the middle class,” he says. So he crafted this citizen initiative.

Proposition 1 proposes $11.25 billion in bonds for a smorgasbord of affordable housing.

This is the political establishment’s creation — Gov. Gavin Newsom, the Democratic-controlled Legislature and housing interests. There’s no organized opposition.

It was dressed up with $1.25 billion in popular CalVet loan bonds for military veterans. They repay their home loans through mortgages, costing the state nothing.

But the remaining $10 billion in bonds would be repaid through the state general fund, costing at least $500 million annually for 25 years.

The measure is mainly designed to generate affordable rentals for poor people. But to assure legislative passage, money was added for affordable student and farmworker housing, plus other goodies.

It’s a lot of money and makes only a small dent in California’s unaffordable housing plague. Moreover, it seems too scattershot.

But it could spare more people from becoming homeless — living in their cars or on sidewalks, ultimately costing taxpayers even more.

Then there’s Proposition 38, the problematic $8.4-billion general fund bond for medical research, including cures for cancer, heart disease and Alzheimer’s.

The hang-up for me and others is that the ballot initiative was crafted to virtually assure that half the bond money would go to one outfit, the UCLA-affiliated California Institute for Immunology and Immunotherapy. The institute was co-founded and is headed by the proposition’s originator and chief backer, billionaire Gary Michelson.

“I know opponents want to create a billionaire boogeyman, but isn’t curing cancer and other terrible diseases exactly what we want billionaires to spend their money on?” says Robin Swanson, a campaign spokesperson.

Sure. But being backed by a billionaire isn’t the problem. It’s being written to substantially benefit one research institute that’s led by the billionaire.

Two cancer survivors and political opposites — conservative consultant Jon Fleischman and liberal consultant Steve Maviglio — co-authored an op-ed that declared:

“Imagine either major political party proposing to borrow billions of dollars and writing the qualifications so narrowly that an organization founded and chaired by a principal campaign benefactor appears positioned to collect half the money. The other party would rightly howl. So should voters.”

They should at least be skeptical.

What else you should be reading

The must-read: California health clinics accuse influential union and its leader of racketeering in civil lawsuit
Danger zone: Newsom creates panel on AI safety regulation, suggests possible ‘kill switch’
The L.A. Times Special: Union power vs. MAGA politics in California’s schools superintendent race

Until next week,
George Skelton

—
Was this newsletter forwarded to you? Sign up here to get it in your inbox.

Within the increasingly specialized field of peptide and metabolic signaling inquiry, AICAR has emerged as a particularly intriguing molecular subject due to its theorized relationship with cellular energy regulation, mitochondrial communication pathways, and adaptive biochemical signaling environments. Although often associated with metabolic research discussions, AICAR occupies a broader scientific position believed to extend beyond simple energy-oriented investigation. Research literature increasingly suggests that the compound may participate in highly nuanced intracellular processes connected to stress adaptation, nutrient sensing, enzymatic communication, and molecular resilience mechanisms across diverse research models.

AICAR, formally known as 5-Aminoimidazole-4-carboxamide ribonucleotide, is structurally related to naturally occurring intermediates involved in purine biosynthesis. Because of this relationship, the molecule has attracted considerable attention in biochemical research environments focused on cellular metabolism and signaling coordination. Investigations purport that AICAR may function as an indirect activator of AMP-activated protein kinase, commonly abbreviated as AMPK, a regulatory enzyme frequently theorized to operate as a cellular energy sensor within the system.

AMPK itself has become a major point of interest in contemporary molecular science because of its proposed involvement in maintaining energetic equilibrium under fluctuating environmental conditions. Research indicates that when energetic stress signals accumulate within cellular systems, AMPK-associated pathways might influence a wide range of downstream biochemical activities involving glucose handling, lipid signaling, mitochondrial turnover, and protein synthesis coordination. Due to AICAR’s theorized interaction with this signaling network, the compound has become deeply integrated into experimental metabolic frameworks.

One of the most discussed properties of AICAR involves its potential relationship with mitochondrial biology. Mitochondria, frequently characterized as central energetic regulators within cellular systems, remain heavily studied due to their possible participation in longevity-associated signaling, oxidative balance, and adaptive cellular responses. Scientific literature suggests that AICAR exposure in controlled research settings may correlate with shifts in mitochondrial biogenesis signaling pathways. It has been hypothesized that this relationship might involve transcriptional regulators such as PGC-1α, a coactivator frequently examined in mitochondrial adaptation research.

Because mitochondrial functionality intersects with numerous branches of biochemical inquiry, AICAR has gradually entered investigative discussions involving endurance-associated metabolic adaptation, cellular resilience environments, and nutrient-sensing systems. Researchers have theorized that the peptide-related compound may provide insight into how cells adapt under resource-limited conditions, particularly in environments characterized by altered energetic availability.

Another area of increasing scientific curiosity involves the potential relationship between AICAR and glucose metabolism pathways. Research indicates that AMPK-associated signaling networks may influence glucose transporter activity and intracellular glucose utilization mechanisms. Within these frameworks, AICAR has been explored as a molecular research tool with the potential of assisting investigators in mapping the biochemical hierarchy involved in carbohydrate-associated signaling environments.

Importantly, these investigations do not merely focus on isolated metabolic reactions. Instead, contemporary scientific inquiry increasingly examines metabolic signaling as part of a larger communication network connecting cellular stress responses, inflammatory mediators, redox balance systems, and transcriptional regulation mechanisms. Within this broader perspective, AICAR may represent more than a singular metabolic modulator. It might instead serve as a biochemical bridge connecting energetic signaling to adaptive cellular communication networks.

Research literature has also explored the possibility that AICAR-associated pathways may intersect with autophagy-related signaling. Autophagy, a tightly regulated intracellular recycling mechanism, remains a prominent topic within longevity-oriented and degenerative-condition research domains. Investigations suggest that AMPK-associated activation environments might influence autophagic coordination through interactions with mTOR-related signaling pathways. Because AICAR appears connected to AMPK-associated activity, scientists have theorized that the molecule may help researchers better understand the balance between anabolic and catabolic cellular states.

The relationship between AICAR and mTOR signaling has generated considerable attention in molecular biology discussions. mTOR, or mechanistic target of rapamycin, is widely recognized as a nutrient-responsive regulatory complex associated with growth-related cellular processes. Research models suggest that energetic stress signaling may suppress certain mTOR-associated activities while promoting cellular conservation mechanisms. Within this context, AICAR has become increasingly valuable as an investigative compound for studying how systems prioritize energetic resources during fluctuating environmental conditions.

Beyond metabolism-centered inquiry, AICAR has also entered conversations surrounding cardiovascular signaling research. Investigations purport that AMPK-associated pathways may participate in vascular regulation, endothelial communication, and oxidative stress adaptation. Some researchers hypothesize that AICAR-related signaling environments could assist in clarifying how cellular systems respond to energetic strain within circulatory tissues. Although many mechanistic questions remain unresolved, the peptide-associated molecule continues to attract interest in biochemical discussions involving cellular oxygen utilization and stress-response coordination.

Neurological research domains have likewise shown growing interest in AMPK-associated signaling pathways. Cellular energy regulation within neurological tissue remains a major focus of contemporary investigation due to the substantial energetic demands associated with neural communication. Scientific discussions increasingly propose that metabolic imbalance, mitochondrial dysfunction, and impaired energetic adaptation might intersect with neurodegenerative signaling environments. Within these frameworks, AICAR has occasionally been examined as a research compound with the potential of illuminating relationships between energetic sensing pathways and neuronal maintenance mechanisms.

Another compelling dimension of AICAR research involves inflammatory signaling environments. Chronic inflammatory activity has become increasingly recognized as a contributing factor across multiple degenerative conditions and longevity-associated biological shifts. Research indicates that AMPK-associated pathways may interact with inflammatory mediators and oxidative stress regulators. Consequently, AICAR has entered exploratory discussions focused on how energetic signaling networks may influence broader cellular communication systems tied to inflammation-associated processes.

Interest in oxidative stress biology has further expanded AICAR’s research relevance. Oxidative balance remains essential for maintaining stable intracellular environments, particularly under metabolically demanding conditions. Some investigations suggest that AMPK-associated signaling might influence antioxidant regulatory pathways and mitochondrial stress adaptation responses. Within these experimental contexts, AICAR has been hypothesized to serve as a useful molecular tool for studying how cells attempt to preserve equilibrium when exposed to fluctuating energetic or oxidative conditions.

Although many mechanistic uncertainties remain unresolved, AICAR persists as a compelling molecular subject whose properties may contribute to a deeper understanding of how energetic regulation influences cellular coordination across complex biological systems. In modern scientific inquiry, where interconnected signaling pathways increasingly define research priorities, compounds such as AICAR may remain valuable tools for exploring the sophisticated architecture underlying metabolic adaptation and cellular communication throughout the system. Researchers interested in more useful peptide data are encouraged to visit www.corepeptides.com.

References